GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.
The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.
GRI Bio, Inc. director David Charles Baker received a grant of 3,935 stock options on November 4, 2026, with an exercise price of $1.43 per share. The options cover common stock, and his reported resulting position was 3,935 options.
GRI Bio, Inc. director Camilla V. Simpson received a grant of 3,935 stock options on November 4, 2026, covering common stock at an exercise price of $1.43 per share. The options expire November 4, 2036.
GRI Bio, Inc. director Roelof Rongen received a grant of 3,935 stock options on November 4, 2026, exercisable for common stock at $1.43 per share. The options vest in four equal quarterly installments and are fully vested on the first anniversary of the grant; they expire November 4, 2036. His directly held options following the grant totaled 3,935.
GRI Bio, Inc. director David Leslie Szekeres received a direct stock option award covering 6,558 shares of common stock on November 4, 2026. The options have a $1.43-per-share exercise price and expire November 4, 2036. The reported post-award option holding is 6,558.
GRI Bio, Inc. reported a nine-month net loss of $5.147 million, versus $9.297 million a year earlier. It used $6.606 million in operating cash, with cash and equivalents of $9.472 million at September 30, 2026. Management estimates cash covers planned operating and capital costs through Q2 2027 only if GRI-0621 work remains preliminary; further studies require substantial additional capital, and the company says substantial doubt exists about its ability to continue as a going concern.
In the Phase 2a IPF trial, 35 patients enrolled; 19 in the GRI-0621 arm and nine placebo recipients completed treatment. The company says the primary endpoint and secondary endpoints measured to date were met, with no treatment-related serious adverse events. Placebo-adjusted change from baseline in FVC was +99 ml in the GRI-0621 arm and +139 ml in those also taking standard of care; a post hoc 1-per-tail Winsorized analysis reported increases of 65 ml and 89 ml, respectively. The FDA granted GRI-0621 Orphan Drug Designation on June 18, 2026.
Disclosure controls were ineffective as of September 30, 2026, due to a previously identified material weakness; revised controls must operate for a sufficient period to remediate it.
GRI Bio, Inc. shares are the subject of a Schedule 13G in which Capuchin Capital Fund LP, its general partner MJL Manager LLC, and MJL's sole control person, Michael Liu, each reported beneficial ownership of 159,378 shares, or 7.3%, with shared voting and dispositive power. The repeated amounts describe the same reported position, not three separate blocks. Each reporting person disclaims beneficial ownership except to the extent of that person's actual pecuniary interest.
GRI Bio, Inc. stockholders approved an amendment and restatement of the 2018 Equity Incentive Plan, increasing the shares reserved for issuance by 546,529 shares and extending the evergreen provision to January 1, 2036. The amendment received 136,205 votes for, 102,978 against and 2,856 abstentions; there were 684,435 broker non-votes.
Stockholders elected W. Marc Hertz, Ph.D. and David Szekeres as Class III directors to serve until the 2029 annual meeting and until their successors are elected and qualified. They also ratified WithumSmith+Brown, PC as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved possible postponement or adjournment to solicit additional proxies if votes were insufficient. A quorum of 926,474 shares, approximately 42.37% of the 2,186,115 eligible shares, was present or represented.
GRI Bio, Inc. is soliciting stockholder votes for its virtual 2026 annual meeting on November 4, 2026. The ballot includes electing W. Marc Hertz, Ph.D. and David Szekeres as Class III directors through the 2029 annual meeting; ratifying WithumSmith+Brown, PC as independent auditor for fiscal 2026; a proposal to increase shares available for issuance under the 2018 Equity Incentive Plan by 546,529 shares and extend its evergreen provision to January 1, 2036; and authority to adjourn or postpone if additional proxies are needed. The board recommends FOR each proposal.
There were 2,186,115 common shares outstanding and entitled to vote as of September 22, 2026. The meeting will be held by live audio webcast at 11:00 a.m. Eastern Time, with voting available online, by telephone, by mail or during the meeting. Reported 2025 total compensation was $1,027,220 for CEO W. Marc Hertz, $584,722 for CFO Leanne Kelly and $579,087 for Chief Scientific Officer Vipin Kumar. The board has five directors, three determined independent, and the chair and CEO roles are separate.
GRI Bio, Inc. (GRI) reported new Phase 2a data for its lead IPF candidate GRI-0621, an oral RARβ/γ agonist, from the randomized, double-blind, placebo-controlled 12‑week GRI‑0621‑IPF‑02 study in 35 idiopathic pulmonary fibrosis patients. The study met its primary objective of safety and tolerability and generated translational biomarker and lung function signals.
Across four independent modalities (RNA sequencing, serum ECM biomarkers, spectral flow cytometry and clinical readouts), GRI-0621 showed direction‑consistent signals supporting nine mechanistic pillars, including immune re‑balancing, fibrolysis, basement‑membrane repair, re‑epithelialization, FVC stabilization, antitussive effect and GI protection. At Week 12, placebo‑adjusted FVC change from baseline was +99 mL overall and +139 mL on background standard antifibrotic therapy, with 39% of treated patients achieving an FVC increase ≥30 mL versus 20% on placebo and a 60% relative reduction in patients with ≥10% FVC decline.
GRI-0621 was well tolerated with no serious treatment‑emergent adverse events in the active arm, fewer cough, dyspnea and diarrhea events than placebo despite higher nintedanib use, and no hepatic, lipid, visual, auditory or neuropsychiatric safety signals. GRI Bio states that the totality of Phase 2a data supports advancing GRI‑0621 into a longer‑duration, 52‑week study.